Saudi Arabia Approves Oncothermia, the Latest Technology in Cancer Treatment
After being approved in over 30 countries, the Saudi Food and Drug Authority (SFDA) approved the use of Oncothermia (modulated electro-hyperthermia, mEHT), the latest complementary cancer treatment technology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170803005553/en/
The treatment gives cancer patients enhanced quality of life, improved survival rates, and comfort during the various stages of treatment as well as promotes their physical and psychological wellbeing.
“Oncothermia is basically developed from the traditional oncological hyperthermia method, one of the oldest methods in fighting diseases,” said Eng. Hani Mohammed Saeed Yamani, General Manager of HYE , Exclusive Agents of Oncothermia devices in GCC.
“Oncothermia does not raise the body temperature. It raises tumor cells temperature to 43⁰ C, while keeping the surrounding healthy tissues at core body temperature, or slightly higher, unlike conventional hyperthermia methods,” he said.
“The new technology uses a modulated electric field of 150 W, with a carrier frequency of 13.56 MHz that is generated by electrodes,” Yamani explained. “The moving electrode is positioned in accordance with the body area being treated, while a second, stationary electrode always remains in a fixed position below the patient.”
Unlike the traditional hyperthermia, Oncothermia targets only the tumor area, leaving the surrounding tissue unaffected. Conductivity in malignant cells is higher than that of normal cells, which means that the electric field applied will reach all malignant cells, increasing their temperature.
Yamani pointed out that the treatment is safe and non-poisonous as it uses low energy levels and frequency fields. It provides various treatment options using Oncothermia for advanced incurable tumors, whether or not they can be surgically removed, as well as recurrent and metastatic cancers and prostate cancer.
Oncothermia is not a stand-alone cancer treatment; it is provided as a complementary treatment. Studies have shown that applying Oncothermia together with radiation therapy or chemotherapy, can be highly effective, and can strongly enhance the effectiveness of other treatments.
Consultants in the Saudi Arabia are currently being introduced to this new technology and its benefits, as well as the research conducted by Prof. András Szász, the inventor of the treatment, to help ease the pain of cancer patients and assist in their healing process.
*Source: AETOS Wire
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum